Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10241MR)

This product GTTS-WQ10241MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10241MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15832MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ12355MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ2913MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ163MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ14379MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ14175MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ7468MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ11748MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-1308
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW